David Borges - Omeros Chief Finance

OMER Stock  USD 7.63  0.86  10.13%   

Executive

David Borges is Chief Finance of Omeros
Age 60
Address The Omeros Building, Seattle, WA, United States, 98119
Phone206 676 5000
Webhttps://www.omeros.com

Omeros Management Efficiency

The company has return on total asset (ROA) of (0.2687) % which means that it has lost $0.2687 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7633) %, meaning that it created substantial loss on money invested by shareholders. Omeros' management efficiency ratios could be used to measure how well Omeros manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/15/2024, Return On Equity is likely to grow to 4.95, while Return On Tangible Assets are likely to drop (0.33). At this time, Omeros' Intangibles To Total Assets are relatively stable compared to the past year.
Omeros currently holds 361.58 M in liabilities. Omeros has a current ratio of 4.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Omeros' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Latha VairavanArcutis Biotherapeutics
N/A
David LiuProtagonist Therapeutics
74
Eric MBAMirum Pharmaceuticals
64
John SchembriAkero Therapeutics
62
Pamela VigMirum Pharmaceuticals
53
Caryn PetersonGossamer Bio
65
Gregory FuestPassage Bio
N/A
Thomas LeggettStoke Therapeutics
47
Matthew JDEnanta Pharmaceuticals
51
Brendan LuuEnanta Pharmaceuticals
49
Catriona YaleAkero Therapeutics
52
Patrick LamyAkero Therapeutics
51
Bethany DudekArcutis Biotherapeutics
N/A
Erin GravesRevolution Medicines
N/A
Jan SmithRevolution Medicines
N/A
Eden FucciPassage Bio
N/A
Jason HoittStoke Therapeutics
46
Elizabeth GordonDesign Therapeutics
N/A
Matthew JDProtagonist Therapeutics
53
Huw NashStoke Therapeutics
57
Carter KingProtagonist Therapeutics
53
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. Omeros Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people. Omeros (OMER) is traded on NASDAQ Exchange in USA. It is located in The Omeros Building, Seattle, WA, United States, 98119 and employs 198 people. Omeros is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Omeros Leadership Team

Elected by the shareholders, the Omeros' board of directors comprises two types of representatives: Omeros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omeros. The board's role is to monitor Omeros' management team and ensure that shareholders' interests are well served. Omeros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omeros' outside directors are responsible for providing unbiased perspectives on the board's policies.
Nadia Dac, VP Officer
Debra MT, Chief Officer
Andreas MD, Chief Officer
Gregory MD, Chairman, CoFounder
Catherine Melfi, Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer
Peter JD, General VP
Michael Jacobsen, Principal Financial Officer, Chief Accounting Officer, VP of Fin. and Treasurer
Pamela MD, CoFounder
Peter Williams, Vice Resources
David Borges, Chief Finance
MD JD, VP Officer

Omeros Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omeros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Omeros

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Omeros position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Omeros will appreciate offsetting losses from the drop in the long position's value.

Moving together with Omeros Stock

  0.85ESPR Esperion TherapeuticsPairCorr
  0.74BMY Bristol Myers SquibbPairCorr

Moving against Omeros Stock

  0.84AMGN Amgen IncPairCorr
  0.75PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr
  0.74AVDL Avadel PharmaceuticalsPairCorr
  0.68JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.66TTOO T2 BiosystmsPairCorr
The ability to find closely correlated positions to Omeros could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Omeros when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Omeros - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Omeros to buy it.
The correlation of Omeros is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Omeros moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Omeros moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Omeros can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Omeros Stock Analysis

When running Omeros' price analysis, check to measure Omeros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omeros is operating at the current time. Most of Omeros' value examination focuses on studying past and present price action to predict the probability of Omeros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omeros' price. Additionally, you may evaluate how the addition of Omeros to your portfolios can decrease your overall portfolio volatility.